Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687117 | 1.00 | MEN1 (0.71) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL6677087 | 1.00 | MEN1 (0.71) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3256450 | 0.87 | MEN1 (0.75) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3256449 | 0.87 | MEN1 (0.75) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1932513 | 0.87 | MEN1 (0.55) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL28006009 | 0.85 | MAPT (0.59) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10414500 | 0.84 | MEN1 (0.52) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10414502 | 0.84 | MEN1 (0.52) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL12226830 | 0.84 | STAT3 (0.74) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10666396 | 0.84 | BACE1 (0.65) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-116234798-A | Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders | 生物药品解决方案有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| CN-106507667-B | Sulfamate derivatives for the prevention or treatment of epilepsy | 比皮艾思药物研发有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3079685-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-28 | — | — | EP | disclosed |
| EP-3079686-B1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-10-24 | — | — | EP | disclosed |
| EP-1603888-A1 | 2-(3-PHENYL-2-PIPERAZINYL-3,4-DIHYDROQUINAZOLINE-4-YL) ACETIC ACIDS AS ANTI-VIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALO VIRUSES | Bayer HealthCare AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-09-08 | — | — | US | disclosed |
| EP-1568695-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | Korea Institute of Science and Technology (KR) | 2005-08-31 | — | — | EP | disclosed |
| EP-1568695-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | Korea Institute of Science and Technology (KR) | 2005-08-31 | — | — | EP | disclosed |
| CN-1660820-A | 3,4-dihydroquinazoline derivatives as t-type calcium channel blockers and method of preparing the same | KOREA INST SCI & TECH (KR) | 2005-08-31 | — | — | CN | disclosed |
| WO-2004099212-A1 | HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004072048-A1 | 2-(3-PHENYL-2-PIPERAZINYL-3,4-DIHYDROQUINAZOLINE-4-YL) ACETIC ACIDS AS ANTI-VIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALO VIRUSES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| US-5652232-A | VIRICIDES, TREATMENT OF RETROVIRUS INFECTIOUS DISEASE; AIDS | SHIONOGI & CO., LTD. (JP) | 1997-07-29 | — | — | US | disclosed |
| EP-0721945-A1 | BENZOLACTAM DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | MEN1 4716/4885KMT2A 388/4885MAPT 573/4885 |
| US-20050197351-A1 | 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same | CACNA1I, CACNA1G, CACNA1H | MEN1 1387/4885KMT2A 1281/4885MAPT 429/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | MEN1 4716/4885KMT2A 388/4885MAPT 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.